SARS-CoV-2 vaccination and myositis in Norway and Sweden
In this nationwide study of >13.6 million person-years in two countries, there were no signs of an increased risk of myositis after SARS-CoV-2 vaccination, neither after the mRNA vaccines nor after the adenoviral vector vaccine.
Authors
- Ingrid E. Lundberg (ORCID: https://orcid.org/0000-0002-6068-9212)
- Jesper Dahl (ORCID: https://orcid.org/0000-0002-0369-9393)
- Anders Sundström (ORCID: https://orcid.org/0000-0003-2337-3371)
- Nicklas Pihlström (ORCID: https://orcid.org/0000-0001-6812-0971)
- German Tapia (ORCID: https://orcid.org/0000-0002-1770-1183)
- Marie Holmqvist (ORCID: https://orcid.org/0000-0001-8996-5260)
- Øystein Karlstad (ORCID: https://orcid.org/0000-0003-1204-787X)
- Nils Feltelius (ORCID: https://orcid.org/0000-0003-1460-4078)
- Rickard Ljung (ORCID: https://orcid.org/0000-0002-0654-4530)
- Marja‐Leena Nurminen
Institutions
- Uppsala University (SE)
- Medical Products Agency (SE)
- Norwegian Institute of Public Health (NO)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1093/rheumatology/keaf609
- Citations
- 1
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.35